PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

June 20, 2025

Primary Completion Date

June 30, 2032

Study Completion Date

June 30, 2035

Conditions
Refractory NeuroblastomaRelapsed NeuroblastomaHigh-Risk Neuroblastoma
Interventions
BIOLOGICAL

PHOX2B PC-CAR T Cells

The PHOX2B PC-CAR T cell investigational product is comprised of autologous human T cells that have been genetically modified to express a a PHOX2B-targeting chimeric antigen receptor (CAR) transgene.

Trial Locations (1)

19104

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

All Listed Sponsors
collaborator

Children's Hospital of Philadelphia

OTHER

collaborator

Alliance for Cancer Gene Therapy

OTHER

collaborator

Children's Cancer Research Fund

OTHER

lead

Stephan Grupp MD PhD

OTHER